BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Thongprasert S. The role of chemotherapy in cholangiocarcinoma. Ann Oncol. 2005;16 Suppl 2:ii93-ii96. [PMID: 15958484 DOI: 10.1093/annonc/mdi712] [Cited by in Crossref: 88] [Cited by in F6Publishing: 73] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Ieta K, Tanaka F, Utsunomiya T, Kuwano H, Mori M. CEACAM6 gene expression in intrahepatic cholangiocarcinoma. Br J Cancer. 2006;95:532-540. [PMID: 16868542 DOI: 10.1038/sj.bjc.6603276] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
2 Bluethner T, Niederhagen M, Caca K, Serr F, Witzigmann H, Moebius C, Mossner J, Wiedmann M. Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach. World J Gastroenterol. 2007;13:4761-4770. [PMID: 17729398 DOI: 10.3748/wjg.v13.i35.4761] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
3 Oliveira IS, Kilcoyne A, Everett JM, Mino-Kenudson M, Harisinghani MG, Ganesan K. Cholangiocarcinoma: classification, diagnosis, staging, imaging features, and management. Abdom Radiol (NY). 2017;42:1637-1649. [PMID: 28271275 DOI: 10.1007/s00261-017-1094-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]
4 Gerhardt T, Milz S, Schepke M, Feldmann G, Wolff M, Sauerbruch T, Dumoulin FL. C-reactive protein is a prognostic indicator in patients with perihilar cholangiocarcinoma. World J Gastroenterol 2006;12:5495-500. [PMID: 17006987 DOI: 10.3748/wjg.v12.i34.5495] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
5 Takahashi H, Ojima H, Shimizu H, Furuse J, Furukawa H, Shibata T. Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma. Jpn J Clin Oncol. 2014;44:570-578. [PMID: 24755544 DOI: 10.1093/jjco/hyu045] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
6 Rattanasinganchan P, Leelawat K, Treepongkaruna SA, Tocharoentanaphol C, Subwongcharoen S, Suthiphongchai T, Tohtong R. Establishment and characterization of a cholangiocarcinoma cell line (RMCCA-1) from a Thai patient. World J Gastroenterol 2006;12:6500-6. [PMID: 17072981 DOI: 10.3748/wjg.v12.i40.6500] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
7 Ma KW, Cheung TT, Leung B, She BWH, Chok KSH, Chan ACY, Dai WC, Lo CM. Adjuvant chemotherapy improves oncological outcomes of resectable intrahepatic cholangiocarcinoma: A meta-analysis. Medicine (Baltimore). 2019;98:e14013. [PMID: 30702559 DOI: 10.1097/md.0000000000014013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
8 Richter JA, Kahaleh M. Photodynamic therapy: Palliation and endoscopic technique in cholangiocarcinoma. World J Gastrointest Endosc. 2010;2:357-361. [PMID: 21173912 DOI: 10.4253/wjge.v2.i11.357] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
9 Vogl TJ, Zangos S, Eichler K, Selby JB, Bauer RW. Palliative hepatic intraarterial chemotherapy (HIC) using a novel combination of gemcitabine and mitomycin C: results in hepatic metastases. Eur Radiol. 2008;18:468-476. [PMID: 17938935 DOI: 10.1007/s00330-007-0781-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
10 Kim ST, Jang KT, Lee SJ, Jang HL, Lee J, Park SH, Park YS, Lim HY, Kang WK, Park JO. Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer. BMC Cancer 2015;15:530. [PMID: 26189560 DOI: 10.1186/s12885-015-1552-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
11 Fu Y, Yang W, Wu W, Yan K, Xing BC, Chen MH. Radiofrequency ablation for postoperative recurrences of intrahepatic cholangiocarcinoma. Chin J Cancer Res. 2011;23:295-300. [PMID: 23359754 DOI: 10.1007/s11670-011-0295-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
12 Yoon H, Min JK, Lee JW, Kim DG, Hong HJ. Acquisition of chemoresistance in intrahepatic cholangiocarcinoma cells by activation of AKT and extracellular signal-regulated kinase (ERK)1/2. Biochem Biophys Res Commun. 2011;405:333-337. [PMID: 21130731 DOI: 10.1016/j.bbrc.2010.11.130] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 5.2] [Reference Citation Analysis]
13 Kiesslich T, Wolkersdörfer G, Neureiter D, Salmhofer H, Berr F. Photodynamic therapy for non-resectable perihilar cholangiocarcinoma. Photochem Photobiol Sci 2009;8:23-30. [PMID: 19247524 DOI: 10.1039/b813183j] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
14 Gusani NJ, Balaa FK, Steel JL, Geller DA, Marsh JW, Zajko AB, Carr BI, Gamblin TC. Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): A single-institution experience. Journal of Gastrointestinal Surgery. 2008;12:129-137. [PMID: 17851723 DOI: 10.1007/s11605-007-0312-y] [Cited by in Crossref: 87] [Cited by in F6Publishing: 68] [Article Influence: 6.2] [Reference Citation Analysis]
15 Shen WF, Zhong W, Liu Q, Sui CJ, Huang YQ, Yang JM. Adjuvant transcatheter arterial chemoembolization for intrahepatic cholangiocarcinoma after curative surgery: retrospective control study. World J Surg. 2011;35:2083-2091. [PMID: 21698503 DOI: 10.1007/s00268-011-1171-y] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 4.1] [Reference Citation Analysis]
16 McKay SC, Unger K, Pericleous S, Stamp G, Thomas G, Hutchins RR, Spalding DR. Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma. HPB (Oxford). 2011;13:309-319. [PMID: 21492330 DOI: 10.1111/j.1477-2574.2010.00286.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
17 Jiao D, Yan Y, Shui S, Wu G, Ren J, Wang Y, Han X. miR-106b regulates the 5-fluorouracil resistance by targeting Zbtb7a in cholangiocarcinoma. Oncotarget 2017;8:52913-22. [PMID: 28881782 DOI: 10.18632/oncotarget.17577] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
18 Schiffman SC, Metzger T, Dubel G, Andrasina T, Kralj I, Tatum C, McMasters KM, Scoggins CR, Martin RC. Precision hepatic arterial irinotecan therapy in the treatment of unresectable intrahepatic cholangiocellular carcinoma: optimal tolerance and prolonged overall survival. Ann Surg Oncol. 2011;18:431-438. [PMID: 20862554 DOI: 10.1245/s10434-010-1333-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
19 Oh MY, Kim H, Choi YJ, Byun Y, Han Y, Kang JS, Sohn H, Lee JM, Kwon W, Jang JY. Conversion surgery for initially unresectable extrahepatic biliary tract cancer. Ann Hepatobiliary Pancreat Surg 2021;25:349-57. [PMID: 34402435 DOI: 10.14701/ahbps.2021.25.3.349] [Reference Citation Analysis]
20 Boueroy P, Hahnvajanawong C, Boonmars T, Saensa-ard S, Wattanawongdon W, Kongsanthia C, Salao K, Wongwajana S, Anantachoke N, Reutrakul V. Synergistic Effect of Forbesione From Garcinia hanburyi in Combination with 5-Fluorouracil on Cholangiocarcinoma. Asian Pac J Cancer Prev 2017;18:3343-51. [PMID: 29286229 DOI: 10.22034/APJCP.2017.18.12.3343] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
21 Qin Y, Cui W, Yang X, Tong B. Kaempferol inhibits the growth and metastasis of cholangiocarcinoma in vitro and in vivo. Acta Biochim Biophys Sin (Shanghai) 2016;48:238-45. [PMID: 26883800 DOI: 10.1093/abbs/gmv133] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 5.2] [Reference Citation Analysis]
22 Hahnvajanawong C, Wattanawongdon W, Chomvarin C, Anantachoke N, Kanthawong S, Sripa B, Reutrakul V. Synergistic effects of isomorellin and forbesione with doxorubicin on apoptosis induction in human cholangiocarcinoma cell lines. Cancer Cell Int 2014;14:68. [PMID: 25866479 DOI: 10.1186/1475-2867-14-68] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
23 Saxena A, Bester L, Chua TC, Chu FC, Morris DL. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol 2010;17:484-91. [PMID: 19876691 DOI: 10.1245/s10434-009-0777-x] [Cited by in Crossref: 120] [Cited by in F6Publishing: 102] [Article Influence: 10.0] [Reference Citation Analysis]
24 Hammill CW, Wong LL. Intrahepatic cholangiocarcinoma: a malignancy of increasing importance. J Am Coll Surg. 2008;207:594-603. [PMID: 18926465 DOI: 10.1016/j.jamcollsurg.2008.04.031] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 3.8] [Reference Citation Analysis]
25 Brito AF, Abrantes AM, Encarnação JC, Tralhão JG, Botelho MF. Cholangiocarcinoma: from molecular biology to treatment. Med Oncol 2015;32:245. [PMID: 26427701 DOI: 10.1007/s12032-015-0692-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
26 Anderson C, Kim R. Adjuvant therapy for resected extrahepatic cholangiocarcinoma: a review of the literature and future directions. Cancer Treat Rev. 2009;35:322-327. [PMID: 19147294 DOI: 10.1016/j.ctrv.2008.11.009] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
27 Williams KJ, Picus J, Trinkhaus K, Fournier CC, Suresh R, James JS, Tan BR. Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study. HPB (Oxford). 2010;12:418-426. [PMID: 20662793 DOI: 10.1111/j.1477-2574.2010.00197.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
28 Poddubskaya EV, Baranova MP, Allina DO, Smirnov PY, Albert EA, Kirilchev AP, Aleshin AA, Sekacheva MI, Suntsova MV. Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma. Exp Hematol Oncol 2018;7:21. [PMID: 30202637 DOI: 10.1186/s40164-018-0113-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
29 Lu Z, Wang J, Zheng T, Liang Y, Yin D, Song R, Pei T, Pan S, Jiang H, Liu L. FTY720 inhibits proliferation and epithelial-mesenchymal transition in cholangiocarcinoma by inactivating STAT3 signaling. BMC Cancer 2014;14:783. [PMID: 25344679 DOI: 10.1186/1471-2407-14-783] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 4.9] [Reference Citation Analysis]
30 Massani M, Nistri C, Ruffolo C, Bonariol R, Pauletti B, Bonariol L, Caratozzolo E, Morana G, Bassi N. Intrahepatic chemotherapy for unresectable cholangiocarcinoma: review of literature and personal experience. Updates Surg. 2015;67:389-400. [PMID: 26468142 DOI: 10.1007/s13304-015-0330-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
31 Mazhar D, Stebbing J, Bower M. Chemotherapy for advanced cholangiocarcinoma: what is standard treatment? Future Oncology 2006;2:509-14. [DOI: 10.2217/14796694.2.4.509] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
32 Möbius C, Demuth C, Aigner T, Wiedmann M, Wittekind C, Mössner J, Hauss J, Witzigmann H. Evaluation of VEGF A expression and microvascular density as prognostic factors in extrahepatic cholangiocarcinoma. Eur J Surg Oncol. 2007;33:1025-1029. [PMID: 17400419 DOI: 10.1016/j.ejso.2007.02.020] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 3.4] [Reference Citation Analysis]
33 Inaba Y, Arai Y, Yamaura H, Sato Y, Najima M, Aramaki T, Sone M, Kumada T, Tanigawa N, Anai H. Phase I/II study of hepatic arterial infusion chemotherapy with gemcitabine in patients with unresectable intrahepatic cholangiocarcinoma (JIVROSG-0301). Am J Clin Oncol. 2011;34:58-62. [PMID: 20177362 DOI: 10.1097/coc.0b013e3181d2709a] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
34 Talabnin C, Talabnin K, Wongkham S. Enhancement of piperlongumine chemosensitivity by silencing heme oxygenase-1 expression in cholangiocarcinoma cell lines. Oncol Lett 2020;20:2483-92. [PMID: 32782567 DOI: 10.3892/ol.2020.11784] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Haidu M, Dobrozemsky G, Schullian P, Widmann G, Klaus A, Weiss H, Margreiter R, Bale R. Stereotactic radiofrequency ablation of unresectable intrahepatic cholangiocarcinomas: a retrospective study. Cardiovasc Intervent Radiol. 2012;35:1074-1082. [PMID: 22006031 DOI: 10.1007/s00270-011-0288-6] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
36 Morise Z, Sugioka A, Tokoro T, Tanahashi Y, Okabe Y, Kagawa T, Takeura C. Surgery and chemotherapy for intrahepatic cholangiocarcinoma. World J Hepatol. 2010;2:58-64. [PMID: 21160974 DOI: 10.4254/wjh.v2.i2.58] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
37 Silakit R, Kitirat Y, Thongchot S, Loilome W, Techasen A, Ungarreevittaya P, Khuntikeo N, Yongvanit P, Yang JH, Kim NH, Yook JI, Namwat N. Potential role of HIF-1-responsive microRNA210/HIF3 axis on gemcitabine resistance in cholangiocarcinoma cells. PLoS One 2018;13:e0199827. [PMID: 29953500 DOI: 10.1371/journal.pone.0199827] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
38 Aljiffry M, Abdulelah A, Walsh M, Peltekian K, Alwayn I, Molinari M. Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature. J Am Coll Surg. 2009;208:134-147. [PMID: 19228515 DOI: 10.1016/j.jamcollsurg.2008.09.007] [Cited by in Crossref: 148] [Cited by in F6Publishing: 128] [Article Influence: 11.4] [Reference Citation Analysis]
39 Egberts J, Schniewind B, Schafmayer C, Kruse M, Sipos B, Fändrich F, Kalthoff H, Tepel J. Establishment of a novel orthotopic xenograft model of human gallbladder carcinoma. Clin Exp Metastasis 2007;24:141-8. [DOI: 10.1007/s10585-007-9058-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
40 Mahavorasirikul W, Viyanant V, Chaijaroenkul W, Itharat A, Na-Bangchang K. Cytotoxic activity of Thai medicinal plants against human cholangiocarcinoma, laryngeal and hepatocarcinoma cells in vitro. BMC Complement Altern Med 2010;10:55. [PMID: 20920194 DOI: 10.1186/1472-6882-10-55] [Cited by in Crossref: 101] [Cited by in F6Publishing: 58] [Article Influence: 9.2] [Reference Citation Analysis]
41 Aljiffry M, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol. 2009;15:4240-4262. [PMID: 19750567 DOI: 10.3748/wjg.15.4240] [Cited by in CrossRef: 173] [Cited by in F6Publishing: 140] [Article Influence: 14.4] [Reference Citation Analysis]
42 Zheng T, Wang J, Chen X, Meng X, Song X, Lu Z, Jiang H, Liu L. Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation. Tumor Biol 2010;31:287-95. [DOI: 10.1007/s13277-010-0035-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
43 Sprinzl MF, Schimanski CC, Moehler M, Schadmand-Fischer S, Galle PR, Kanzler S. Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report. BMC Cancer. 2006;6:190. [PMID: 16846514 DOI: 10.1186/1471-2407-6-190] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
44 Trachu N, Sirachainan E, Larbcharoensub N, Rattanadech W, Detarkom S, Monnamo N, Kamprerasart K, MunTham D, Sukasem C, Reungwetwattana T. Molecular alterations and clinical prognostic factors for cholangiocarcinoma in Thai population. Onco Targets Ther 2017;10:4955-68. [PMID: 29066915 DOI: 10.2147/OTT.S143982] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
45 Marzioni M, Fava G, Benedetti A. Nervous and Neuroendocrine regulation of the pathophysiology of cholestasis and of biliary carcinogenesis. World J Gastroenterol 2006;12:3471-80. [PMID: 16773704 DOI: 10.3748/wjg.v12.i22.3471] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
46 Sumsakul W, Mahavorasirikul W, Na-Bangchang K. Inhibitory Activities of Thai Medicinal Plants with Promising Activities Against Malaria and Cholangiocarcinoma on Human Cytochrome P450. Phytother Res 2015;29:1926-33. [PMID: 26490449 DOI: 10.1002/ptr.5485] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
47 Chen L, Chen C, Yen Y, Tam KW. Chemotherapy for advanced biliary tract carcinoma: A meta-analysis of randomized controlled trials. Medicine (Baltimore) 2016;95:e4584. [PMID: 27537589 DOI: 10.1097/MD.0000000000004584] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
48 Brunner TB, Eccles CL. Radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma. Strahlenther Onkol 2010;186:672-80. [PMID: 21136029 DOI: 10.1007/s00066-010-2161-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
49 Paholpak P, Sirichativapee W, Wisanuyotin T, Kosuwon W, Jeeravipoolvarn P. Prevalence of known and unknown primary tumor sites in spinal metastasis patients. Open Orthop J 2012;6:440-4. [PMID: 23115604 DOI: 10.2174/1874325001206010440] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
50 Li J, Huang L, Li Z, Zhong X, Tai S, Jiang X, Cui Y. Functions and roles of long noncoding RNA in cholangiocarcinoma. J Cell Physiol. 2019;234:17113-17126. [PMID: 30888066 DOI: 10.1002/jcp.28470] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
51 LaRocca RV, Hicks MD, Mull L, Foreman B. Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report. J Gastrointest Cancer 2007;38:154-6. [PMID: 19089671 DOI: 10.1007/s12029-008-9028-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
52 Kim DH, Im BN, Hwang HS, Na K. Gemcitabine-loaded DSPE-PEG-PheoA liposome as a photomediated immune modulator for cholangiocarcinoma treatment. Biomaterials 2018;183:139-50. [PMID: 30170256 DOI: 10.1016/j.biomaterials.2018.08.052] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
53 Ibrahim SM, Mulcahy MF, Lewandowski RJ, Sato KT, Ryu RK, Masterson EJ, Newman SB, Benson A, Omary RA, Salem R. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer. 2008;113:2119-2128. [PMID: 18759346 DOI: 10.1002/cncr.23818] [Cited by in Crossref: 137] [Cited by in F6Publishing: 107] [Article Influence: 10.5] [Reference Citation Analysis]
54 Farhat MH, Shamseddine AI, Tawil AN, Berjawi G, Sidani C, Shamseddeen W, Barada KA. Prognostic factors in patients with advanced cholangiocarcinoma: role of surgery, chemotherapy and body mass index. World J Gastroenterol 2008;14:3224-30. [PMID: 18506930 DOI: 10.3748/wjg.14.3224] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
55 Shimoda M, Iso Y, Tomita S, Fujimori T, Murakami K, Sawada T, Kubota K. Middle bile duct cancer with portal vein tumor thrombus. World J Surg Oncol 2008;6:48. [PMID: 18471304 DOI: 10.1186/1477-7819-6-48] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
56 Guion-Dusserre JF, Lorgis V, Vincent J, Bengrine L, Ghiringhelli F. FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma. World J Gastroenterol. 2015;21:2096-2101. [PMID: 25717243 DOI: 10.3748/wjg.v21.i7.2096] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 36] [Article Influence: 6.7] [Reference Citation Analysis]
57 Kim ST, Jang KT, Lee J, Jang HM, Choi HJ, Jang HL, Park SH, Park YS, Lim HY, Kang WK, Park JO. Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer. Transl Oncol 2015;8:40-6. [PMID: 25749176 DOI: 10.1016/j.tranon.2014.12.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
58 Yoon H, Min JK, Lee DG, Kim DG, Koh SS, Hong HJ. L1 cell adhesion molecule and epidermal growth factor receptor activation confer cisplatin resistance in intrahepatic cholangiocarcinoma cells. Cancer Lett 2012;316:70-6. [PMID: 22088438 DOI: 10.1016/j.canlet.2011.10.024] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
59 Liu RQ, Shen SJ, Hu XF, Liu J, Chen LJ, Li XY. Prognosis of the intrahepatic cholangiocarcinoma after resection: hepatitis B virus infection and adjuvant chemotherapy are favorable prognosis factors. Cancer Cell Int. 2013;13:99. [PMID: 24139471 DOI: 10.1186/1475-2867-13-99] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
60 Hong K, Geschwind JH. Locoregional Intra-arterial Therapies for Unresectable Intrahepatic Cholangiocarcinoma. Seminars in Oncology 2010;37:110-7. [DOI: 10.1053/j.seminoncol.2010.03.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
61 Hahnvajanawong C, Chaiyagool J, Seubwai W, Bhudhisawasdi V, Namwat N, Khuntikeo N, Sripa B, Pugkhem A, Tassaneeyakul W. Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil. World J Gastroenterol 2012;18:3955-61. [PMID: 22912546 DOI: 10.3748/wjg.v18.i30.3955] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
62 Li Y, Li D, Chen J, Wang S. A polysaccharide from Pinellia ternata inhibits cell proliferation and metastasis in human cholangiocarcinoma cells by targeting of Cdc42 and 67kDa Laminin Receptor (LR). Int J Biol Macromol 2016;93:520-5. [PMID: 27576948 DOI: 10.1016/j.ijbiomac.2016.08.069] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
63 Eitaki M, Yamamori T, Meike S, Yasui H, Inanami O. Vincristine enhances amoeboid-like motility via GEF-H1/RhoA/ROCK/Myosin light chain signaling in MKN45 cells. BMC Cancer. 2012;12:469. [PMID: 23057787 DOI: 10.1186/1471-2407-12-469] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
64 Roth JA, Carlson JJ. Cost-Effectiveness of Gemcitabine + Cisplatin vs. Gemcitabine Monotherapy in Advanced Biliary Tract Cancer. J Gastrointest Canc 2012;43:215-23. [DOI: 10.1007/s12029-010-9242-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
65 Yang L, Shan J, Shan L, Saxena A, Bester L, Morris DL. Trans-arterial embolisation therapies for unresectable intrahepatic cholangiocarcinoma: a systematic review. J Gastrointest Oncol 2015;6:570-88. [PMID: 26487951 DOI: 10.3978/j.issn.2078-6891.2015.055] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
66 Socoteanu MP, Mott F, Alpini G, Frankel AE. c-Met targeted therapy of cholangiocarcinoma. World J Gastroenterol. 2008;14:2990-2994. [PMID: 18494048 DOI: 10.3748/wjg.14.2990] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
67 Pignochino Y, Sarotto I, Peraldo-Neia C, Penachioni JY, Cavalloni G, Migliardi G, Casorzo L, Chiorino G, Risio M, Bardelli A. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer. 2010;10:631. [PMID: 21087480 DOI: 10.1186/1471-2407-10-631] [Cited by in Crossref: 110] [Cited by in F6Publishing: 95] [Article Influence: 10.0] [Reference Citation Analysis]
68 Morise Z, Sugioka A, Hoshimoto S, Kato T, Tanahashi Y, Ikeda M, Kagawa T. Patient with advanced intrahepatic cholangiocarcinoma with long-term survival successfully treated with a combination of surgery and chemotherapy. J Hepatobiliary Pancreat Surg 2008;15:545-8. [DOI: 10.1007/s00534-007-1270-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
69 Ojima H, Yoshikawa D, Ino Y, Shimizu H, Miyamoto M, Kokubu A, Hiraoka N, Morofuji N, Kondo T, Onaya H. Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment. Cancer Sci. 2010;101:882-888. [PMID: 20088962 DOI: 10.1111/j.1349-7006.2009.01462.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
70 Talreja JP, Kahaleh M. Photodynamic therapy for cholangiocarcinoma. Gut Liver. 2010;4 Suppl 1:S62-S66. [PMID: 21103297 DOI: 10.5009/gnl.2010.4.s1.s62] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
71 Poruk KE, Pawlik TM, Weiss MJ. Perioperative Management of Hilar Cholangiocarcinoma. J Gastrointest Surg 2015;19:1889-99. [PMID: 26022776 DOI: 10.1007/s11605-015-2854-8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 27] [Article Influence: 6.7] [Reference Citation Analysis]
72 Zhao X, Zhang C, Zhou H, Xiao B, Cheng Y, Wang J, Yao F, Duan C, Chen R, Liu Y, Feng C, Li H, Li J, Dai R. Synergistic antitumor activity of the combination of salubrinal and rapamycin against human cholangiocarcinoma cells. Oncotarget 2016;7:85492-501. [PMID: 27863431 DOI: 10.18632/oncotarget.13408] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 5.7] [Reference Citation Analysis]
73 Lee J, Park SH, Chang HM, Kim JS, Choi HJ, Lee MA, Jang JS, Jeung HC, Kang JH, Lee HW, Shin DB, Kang HJ, Sun JM, Park JO, Park YS, Kang WK, Lim HY. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012;13:181-188. [PMID: 22192731 DOI: 10.1016/s1470-2045(11)70301-1] [Cited by in Crossref: 259] [Cited by in F6Publishing: 126] [Article Influence: 25.9] [Reference Citation Analysis]